Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. The company is headquartered in Chicago, Illinois.
| Revenue (TTM) | $335.41M |
| Gross Profit (TTM) | $290.38M |
| EBITDA | $48.77M |
| Operating Margin | 5.62% |
| Return on Equity | -617.00% |
| Return on Assets | 6.13% |
| Revenue/Share (TTM) | $1.99 |
| Book Value | $0.08 |
| Price-to-Book | 48.96 |
| Price-to-Sales (TTM) | 8.26 |
| EV/Revenue | 6.74 |
| EV/EBITDA | 42.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 28.70% |
| Shares Outstanding | $182.32M |
| Float | $176.07M |
| % Insiders | 3.03% |
| % Institutions | 62.44% |
Volatility is currently expanding
Xeris Biopharma (XERS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to break-even earnings per share a year ago.
Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced its financial results and business highlights for the third quarter ended September 30, 2026. “As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve tha.
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced it will release its financial results and business highlights for the third quarter ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 5, 2026. Management will host a conference call.
Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma , Bloomberg News reported on Tuesday, citing people familiar with the matter.
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company's Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism. The XP-8121 webinar will take place on Wednesday, Septemb.
Xeris Biopharma Holdings, Inc. achieved record 2024 revenues of $203M, up 24%, with robust growth across all three commercial products. 2025 revenue guidance of $255M–$275M implies 30% growth for XERS at midpoint, supporting a forward P/S ratio of ~3.4x and fair valuation. XP-8121, a once-weekly injectable levothyroxine, targets a $1B+ U.S. market and could be a future blockbuster pending Phase 3 trial initiation.
Xeris Biopharma NASDAQ: XERS reported second-quarter total revenue of $92.1 million, up 29% from a year earlier, as net product revenue increased 34% to $91 million. The company raised the low end of its full-year 2026 revenue outlook, now forecasting total revenue of $385 million to $390 million.
Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on XERS and any ticker you trade — then tracks every position and per-strategy win rate.
